Medication Nonadherence Is Associated with Increased Subsequent Acute Care Utilization among Medicaid Beneficiaries with Systemic Lupus Erythematosus

Arthritis Care and Research

Volumn 67, Issue 12, 2015, Pages 1712-1721

  Feldman, Candace H ^a   Yazdany, Jinoos ^b   Guan, Hongshu ^a   Solomon, Daniel H ^a   Costenbader, Karen H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; ANTIRHEUMATIC AGENT;

ADULT; AGE; AGE DISTRIBUTION; ARTICLE; BLACK PERSON; CAUCASIAN; CONTROLLED STUDY; DRUG USE; EMERGENCY CARE; ETHNICITY; FEMALE; HEALTH CARE UTILIZATION; HISPANIC; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT COMPLIANCE; RISK ASSESSMENT; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; CHI SQUARE DISTRIBUTION; FACTUAL DATABASE; HEALTH CARE PLANNING; HOSPITAL EMERGENCY SERVICE; INSURANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICATION COMPLIANCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; TIME FACTOR; UNITED STATES; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; INSURANCE BENEFITS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84956675821     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22636     Document Type: Article

References (56)

1. Osterberg L, Blaschke T., Adherence to medication. N Engl J Med 2005; 353: 487-97.
2. Marcum ZA, Sevick MA, Handler SM., Medication nonadherence: A diagnosable and treatable medical condition. JAMA 2013; 309: 2105-6.
3. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4.
4. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al., Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69: 2083-9.
5. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al., Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7.
6. Marengo MF, Waimann CA, de Achaval S, Zhang H, Garcia-Gonzalez A, Richardson MN, et al., Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus 2012; 21: 1158-65.
7. Koneru S, Kocharla L, Higgins GC, Ware A, Passo MH, Farhey YD, et al., Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 2008; 14: 195-201.
8. Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, et al., Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum 2007; 57: 1000-6.
9. Daleboudt GM, Broadbent E, McQueen F, Kaptein AA., Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63: 342-50.
10. Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al., Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 240-6.
11. Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D., Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum 2002; 47: 630-8.
12. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M., Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med 1991; 91: 345-53.
13. Adler M, Chambers S, Edwards C, Neild G, Isenberg D., An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) 2006; 45: 1144-7.
14. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA., Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 37-47.
15. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ., Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: A five-year analysis of a large Medicaid population. Arthritis Rheum 2009; 61: 755-63.
16. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM., Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis Rheum 2007; 56: 2092-4.
17. Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al., Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 1788-95.
18. Yazdany J, Marafino BJ, Dean ML, Bardach NS, Duseja R, Ward MM, et al., Thirty-day hospital readmissions in systemic lupus erythematosus: Predictors and hospital- and state-level variation. Arthritis Rheumatol 2014; 66: 2828-36.
19. Rasmussen JN, Chong A, Alter DA., Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177-86.
20. Esposito D, Bagchi AD, Verdier JM, Bencio DS, Kim MS., Medicaid beneficiaries with congestive heart failure: Association of medication adherence with healthcare use and costs. Am J Manag Care 2009; 15: 437-45.
21. Rojas-Serrano J, Cardiel MH., Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome: A cohort study. Lupus 2000; 9: 601-6.
22. The Henry J. Kaiser Foundation. Medicaid: A primer. Key information on the nation's health coverage program for low-income people. 2013. URL: Http://kff.org/medicaid/issue-brief/medicaid-a-primer/.
23. US Department of Health and Human Services. A profile of older Americans. 2012. URL: Http://www.aoa.gov/Aging-Statistics/Profile/2012/docs/2012profile.pdf.
24. Hiraki LT, Feldman CH, Liu J, Alarcon GS, Fischer MA, Winkelmayer WC, et al., Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum 2012; 64: 2669-76.
25. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcon GS, et al., Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 2013; 65: 753-63.
26. Solomon DH, Lunt M, Schneeweiss S., The risk of infection associated with tumor necrosis factor α antagonists: Making sense of epidemiologic evidence. Arthritis Rheum 2008; 58: 919-28.
27. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA., Adherence, discontinuation, and switching of biologic therapies in Medicaid enrollees with rheumatoid arthritis. Value Health 2010; 13: 805-12.
28. Hess LM, Raebel MA, Conner DA, Malone DC., Measurement of adherence in pharmacy administrative databases: A proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-8.
29. Blandford L, Dans PE, Ober JD, Wheelock C., Analyzing variations in medication compliance related to individual drug, drug class and prescribing physician. J Manag Care Pharm 1999; 5: 47-51.
30. Shenolikar RA, Balkrishnan R, Camacho FT, Whitmire JT, Anderson RT., Race and medication adherence in Medicaid enrollees with type-2 diabetes. J Natl Med Assoc 2006; 98: 1071-7.
31. Svarstad BL, Shireman TI, Sweeney JK., Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001; 52: 805-11.
32. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al., Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692-9.
33. Chronic Conditions Data Warehouse. Medicaid enrollment by race: 1999-2007. 2015. URL: Http://www.ccwdata.org/summary-statistics/demographics/index.htm.
34. Ward MM., Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis. J Rheumatol 2007; 34: 2024-7.
35. Ward MM., Development and testing of a systemic lupus-specific risk adjustment index for in-hospital mortality. J Rheumatol 2000; 27: 1408-13.
36. Hope CJ, Wu J, Tu W, Young J, Murray MD., Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm 2004; 61: 2043-9.
37. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al., Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836-41.
38. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al., Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-7.
39. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al., Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006; 113: 2803-9.
40. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS., Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-30.
41. Dragomir A, Cote R, Roy L, Blais L, Lalonde L, Berard A, et al., Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48: 418-25.
42. Chambers S, Raine R, Rahman A, Hagley K, De Ceulaer K, Isenberg D., Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica. Lupus 2008; 17: 761-9.
43. Oliveira-Santos M, Verani JF, Klumb EM, Albuquerque EM., Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus 2011; 20: 320-9.
44. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al., Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-44.
45. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C., The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 2000; 12: 387-98.
46. Gomez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcon GS, Costenbader KH., Racial/ethnic variation in all-cause mortality among United States Medicaid recipients with systemic lupus erythematosus: A Hispanic and Asian paradox. Arthritis Rheumatol 2015; 67: 752-60.
47. Raven MC, Billings JC, Goldfrank LR, Manheimer ED, Gourevitch MN., Medicaid patients at high risk for frequent hospital admission: Real-time identification and remediable risks. J Urban Health 2009; 86: 230-41.
48. Billings J, Mijanovich T., Improving the management of care for high-cost Medicaid patients. Health Aff (Millwood) 2007; 26: 1643-54.
49. Suissa S., Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-9.
50. Franklin JM, Shrank WH, Pakes J, Sanfelix-Gimeno G, Matlin OS, Brennan TA, et al., Group-based trajectory models: A new approach to classifying and predicting long-term medication adherence. Med Care 2013; 51: 789-96.
51. Ho PM, Bryson CL, Rumsfeld JS., Medication adherence: Its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-35.
52. Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, et al., Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosis. Med Care 2009; 47: 334-41.
53. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, et al., Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect. Am J Epidemiol 2007; 166: 348-54.
54. Shrank WH, Patrick AR, Brookhart MA., Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J Gen Intern Med 2011; 26: 546-50.
55. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC., An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008; 46: 1125-33.
56. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al., Measuring concurrent adherence to multiple related medications. Am J Manag Care 2009; 15: 457-64.